Linda Vahdat, MD, MBA

home / authors / linda-vahdat-md-mba

Articles

Linda Vahdat, MD, MBA

Dr Vahdat on the Role of Copper Depletion in Reducing Metastatic Disease Risk in TNBC

Linda Vahdat, MD, MBA
August 28th 2024

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.

Read More

Linda Vahdat, MD, MBA

Dr Vahdat on Recent Data on ADCs in Metastatic TNBC

Linda Vahdat, MD, MBA
August 5th 2024

Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
OncLive
Published: September 12th 2024 | Updated: September 18th 2024
State of the Science Summit - Breast Cancer: Chaired by Jairam Krishnamurthy, MD, FACP
Peter Schmid, MD, PhD, Barts College
Published: September 15th 2024 | Updated: September 18th 2024
Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC